Should you buy XOMA Royalty stock now?
The technical signal for XOMA Royalty is currently NEUTRAL. XOMA Royalty trades at $40.17 as of 8/6/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is negative (bearish trend) at -0.443 with falling momentum (signal: -0.037); RSI is at 34.3 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $39.00 is 2.9% below the current price. This is a technical observation based on current data, not investment advice.
What is the price target for XOMA Royalty stock?
The average analyst price target for XOMA Royalty is $39.00. The current price is $40.17, which gives a downside of 2.9%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $35.10 and $42.90.
Is XOMA Royalty a dividend stock?
No, XOMA Royalty does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of XOMA Royalty stock?
XOMA Royalty is rated as a stock with high risk. the annual standard deviation is 51.5%, which classifies the stock as high risk.
Is XOMA Royalty overvalued?
XOMA Royalty is considered fairly valued – the price is close to the analyst price target. XOMA Royalty has the following valuation ratios: a P/E ratio of 25.6 (moderately to highly valued), a P/S ratio of 14.6, a P/B ratio of 6.3. The stock trades close to the analyst price target and is considered fairly valued.
Is XOMA Royalty overbought?
No, XOMA Royalty is not overbought. RSI is at 34.3 (neutral zone). The technical indicators show: RSI is at 34.3 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 4.5% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next XOMA Royalty earnings report?
XOMA Royalty reports its next earnings on August 12, 2026. The stock currently trades at $40.17. With a P/E ratio of 25.6, the market will be watching closely whether earnings meet expectations. The RSI is at 34.3, so the report can reinforce the current technical trend.
Is XOMA Royalty shorted?
Yes, XOMA Royalty is shorted with 9.3% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. Data is updated daily based on official filings with the SEC.
Are insiders buying XOMA Royalty stock?
Yes, insiders are net buyers of XOMA Royalty – they are buying more shares than they are selling. Over the last 3 months, insiders have made 1 purchases and 0 sales. On a net basis, 9,321,390 $ worth of shares were bought. Across the last 20 reported transactions, the split is 14 purchases and 6 sales, with a net 802,028 $ sold. Active buyers include BVF PARTNERS L P/IL, LIMBER JOSEPH M, WYSZOMIERSKI JACK L and others. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is XOMA Royalty a good stock?
Based on our total score, XOMA Royalty is rated as a good stock with a total score of 64 out of 100. The stock scores above average on value, quality and momentum – it is among the top 36% in our database. The score is made up of Value: 35/100, Quality: 81/100, Momentum: 75/100. In addition: technical signal: Hold. Whether XOMA Royalty is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for XOMA Royalty stock?
The outlook for XOMA Royalty based on current data: the average analyst price target is $39.00 (-2.9%); the next earnings report is due on 8/12/2026, which can move the price; the P/E ratio is 25.6 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is XOMA Royalty stock falling?
XOMA Royalty is falling right now. The technical indicators show: the price is 4.5% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 9.3% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can XOMA Royalty go?
The average analyst price target for XOMA Royalty is $39.00, which is 2.9% below the current price of $40.17. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can XOMA Royalty fall?
We lack enough history to give a specific floor for XOMA Royalty. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does XOMA Royalty do?
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate XOMA Royalty as an investment.
Did XOMA Royalty raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from XOMA Royalty. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is XOMA Royalty making money or losing money?
Yes, XOMA Royalty is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 69.6% — which is excellent. At a P/E ratio of 25.6, you currently pay 25.6 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can XOMA Royalty go bankrupt?
The bankruptcy risk of XOMA Royalty is rated as elevated. Altman Z2 (a model for assessing financial distress) is -10.63 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 170% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does XOMA Royalty have a lot of debt?
Yes, XOMA Royalty has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 170%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can XOMA Royalty service its debt? Can service its debt, but it weighs on the company — the interest coverage ratio (how many times earnings can cover interest payments) is 2.3x, and net debt equals 3.7 years of earnings (EBITDA).
